D-Dimer and TAT Measurement in Patients with Deep Venous Thrombosis: Utility in Diagnosis and Judgement of Anticoagulant Treatment Effectiveness

Summary

The plasma levels of thrombin-antithrombin III-complexes (TAT) and the fibrin split product D-Dimer were measured in 39 patients with phlebographically proven acute DVT: 34 patients had proximal DVT, 5 had calf DVT The sensitivity of D-Dimer and TAT measurements in the diagnosis of proximal DVT was found to be dependent on the duration of symptoms: 0 to 7 days (n = 27): elevated D-Dimer levels (>120 ng/ml) = 1, D-Dimer Latex test positive (>500 ng/ml) = 1, elevated TAT levels (>6 ng/ml) = 0.88. Eight to 14 days (n = 7): elevated D-Dimer levels = 1, D-Dimer Latex test positive = 0.33, elevated TAT levels = 0.66; specificity: elevated D-Dimer: 0.48, D-Dimer Latex test: 1, elevated TAT: 0.76. Calf DVT patients (n = 5) had elevated D-Dimer levels, negative Latex tests and 3 of them had normal TAT values. Hemostatic and fibrinolytic parameters were also determined in 13 patients during heparin treatment of proximal DVT. Elevated D-Dimer and TAT levels rapidly decreased after initiation of anticoagulant therapy. In 2 of 13 patients a marked increase in D-Dimer and TAT levels was observed in periods of ineffective heparinization, documented by normal or only slightly prolonged thrombin clotting times. We conclude from our results that 1) D-Dimer El A measurement, in contrast to TAT measurement, shows a very high sensitivity in the diagnosis of DVT, 2) due to low specificity this test can only be used to exclude thrombosis in patients with suspected DVT, and 3) the determination of the plasma levels of D-Dimer and TAT may be useful for judging the effect of anticoagulant treatment on thrombotic processes.

• References

• 1 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-106
• 2 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemostas 1983; 50: 591-594
• 3 Koppert PW, Hoegee-de NobelE, Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemostas 1988; 59: 310-315
• 4 Greenberg CS, Devine DV, McCrae KM. Measurement of plasma fibrin D-Dimer levels with the use of a monoclonal antibody com-plexed to Latex beads. Am J Clin Pathol 1987; 87: 94-100
• 5 Bauer KA, Rosenberg DR. Thrombin generation in acute pro-myelocytic leukemia. Blood 1984; 64: 791-796
• 6 Rowbotham BJ, Carroll P, Whitaker AN, Bunce IH, Cobcroft RG, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ. Measurement of crosslinked fibrin derivatives - use in the diagnosis of venous thrombosis. Thromb Haemostas 1987; 57: 59-61
• 7 Heaton DC, Billings JD, Hickton CM. Assessment of D-Dimer assays for the diagnosis of deep vein thrombosis. J Lab Clin Med 1987; 110: 588-591
• 8 Bounameaux H, Schneider PA, Reber G, de Moerloose P, Krahen-buhl B. Measurement of plasma D-Dimer for diagnosis of deep venous thrombosis. Am J Clin Pathol 1989; 91: 82-85
• 9 Goldhaber SZ, Vaughan DE, Tumeh SS, Loscalzo J. Utility of crosslinked fibrin degradation products in the diagnosis of pulmonary embolism. Am Heart J 1988; 116: 505-508
• 10 Bounameaux H, Slosman D, de Moerloose Ph, Reber G. Diagnostic value of plasma D-Dimer in suspected pulmonary embolism. Lancet 1988; ii: 628-629 (Letter)
• 11 Bridey F, Philipotteau C, Dreyfus M, Simonneau G. Plasma D-Dimer and pulmonary embolism. Lancet 1989; i: 791-792 (Letter)
• 12 Speiser W, Leitha T, Dudczak R, Lechner K. Plasma D-Dimer levels in patients with pulmonary embolism. Lancet 1989; i: 792 (Letter)
• 13 Hafter R, Schrock R, von HugoR, Graeff H. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D-Dimer using El A and latex test. Scand J Clin Lab Invest 1985; 45: 137-144
• 14 Korninger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41: 527-535
• 15 Speiser W, Bowry S, Anders E, Binder BR, Miiller-Berghaus G. Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-CAP) in plasma, platelets and endothelial cells. Thromb Res 1986; 44: 503-515
• 16 Shifman MA, Pizzo SV. The in vivo metabolism of antithrombin III and antithrombin III complexes. J Biol Chem 1982; 257: 3243-3247
• 17 Franks JJ, Kirsch RE, Kao B, Kloppel TM. Fibrinogen and fibrinogen related peptides in cancer. In: Pathophysiology of Plasma Protein Metabolism Mariani G. (ed) MacMillan London: 1984: 265-269
• 18 Paramo JA, de Boer A, Colucci M, Jonker J JC, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep venous thrombosis. Thromb Haemostas 1985; 54: 725
• 19 Juhan-Vague I, Aillaud MF, De Cock F, Philip-Joet C, Arnaud C, Serradimigni A, Collen D. The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant protein. Progr Fibrinolysis 1985; 7: 146-148
• 20 Penscher FW, Van Aken WG, Flier O ThN, Stoepman-van DalenE A, Cremer-Goote TM, Van Mourik JA. Effect of anticoagulant treatment measured by fibrinopeptide A (fp A) in patients with venous thrombo-embolism. Thromb Res 1980; 18: 33-43
• 21 Yudelman I, Greenberg J. Factors affecting fibrinopeptide-A levels in patients with venous thromboembolism during anticoagulant therapy. Blood 1982; 59: 787-792